Stockscreener 앱 받기
63.81
0.05%
-0.03
시간 외 거래:
63.81
전일 마감가:
$63.84
열려 있는:
$63.39
하루 거래량:
1.64M
Relative Volume:
1.27
시가총액:
$7.97B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
21.13
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-0.33%
1개월 성능:
+7.88%
6개월 성능:
+11.48%
1년 성능:
+56.86%
1일 변동 폭
$62.60
$64.07
1주일 범위
$62.60
$65.03
52주 변동 폭
$37.73
$66.00
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
63.81 | 7.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters.com
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Zacks Research Issues Negative Outlook for HALO Earnings - Defense World
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN
Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN
Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada
High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance
JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India
Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal
Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India
Halozyme Therapeutics Director Sells 5,000 Shares - TradingView
Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock - MarketBeat
Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock - MarketBeat
Los Angeles Capital Management LLC Has $4.42 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics SVP sells $1.26 million in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Michael Labarre Sells Shares of Halozyme The - GuruFocus.com
Halozyme Therapeutics SVP sells shares totaling $1.26 million By Investing.com - Investing.com South Africa
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):